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ABSTRACT
Purpose: Chlamydia trachomatis and Mycoplasma hominis, Mycoplasma genitalium, and Ureaplasma urealyticum are 
associated with various diseases of the urogenital tract, but they are usually not detected by routine microbiological diagnosis. 
To determine the occurrence of Chlamydia trachomatis, Mycoplasma hominis, Mycoplasma genitalium, and Ureaplasma 
urealyticum in patients with sterile pyuria.
Material/Methods: Sterile pyuria urine samples collected during the period from February 2006 to April 2007 were tested 
by polymerase chain reaction (PCR) for the presence of C. trachomatis, M. hominis, M. genitalium, and U. urealyticum using 
specific primers for each species. A total of 200 sterile pyuria samples selected from about 2400 urine samples attending the 
genitourinary clinic at Al-Shifa hospital, Gaza, during the period February 2006 to April 2007 and were analyzed for routine 
urine examination and cultured on MacConkey agar, blood agar, and sabouraud agar to detect the presence of bacteria and 
Candida. The 200 samples (96 male, 104 female; aged ≥18 years) containing more than 10 leukocytes / HPF and negative for 
culture (showing no significant growth after 24 hr) were tested by PCR for C. trachomatis and M. hominis, M. genitalium, and 
U. urealyticum.
Results: C. trachomatis was detected in 20 samples (10%), U. urealyticum in 10 samples (5%), M. hominis in 6 samples (3%) 
and M. genitalium in 2 samples (1%). The difference in occurrence of C. trachomatis was statistically insignificant between 
males and females (P=0.509), but it was significant (P=0.008) for U. urealyticum. M. hominis was detected only in samples 
collected from female patients. On the other hand, M. genitalium was detected only in men.
Conclusion: PCR testing of sterile pyuria showed a significant number of C. trachomatis, Mycoplasma, and Ureaplasma 
infections. Consequently, PCR is recommended for the detection of those microorganisms in the urine samples of sterile pyuria 
patients.
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INTRODUCTION
Sterile pyuria is a condition in which white blood cells (WBCs) 
are present in the urine (≥10/HPF) without bacteria growing in 
standard cultures [1].
Sterile pyuria is  associated with a number of infective 
agents including viruses, fungi and  atypical or fastidious 
organisms such as Chlamydia trachomatis, Mycoplasmas, 
and Ureaplasmas [2]. Mycoplasmas, Ureaplasmas and C. 
trachomatis are associated with various diseases of the 
genitourinary  tract, but they are usually not detected  by routine 
microbiological diagnosis [3]. Molecular genetic techniques, 
such as polymerase chain reaction (PCR), are useful for the 
identification of microorganisms that are difficult to cultivate 
and for those that grow slowly [4].
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C. trachomatis infection of the lower genital tract is one 
of  the most prevalent sexually transmitted diseases (STDs) 
worldwide [5]. According to the World Health Organization 
(WHO), approximately 89 million people are newly infected 
with  C. trachomatis infections  annually worldwide [6]. C. 
trachomatis infection, if not treated in an early stage, can lead 
to severe sequelae, such as pelvic inflammatory  disease (PID), 
ectopic pregnancy and tubal infertility [7].
However, 50-80% of infected men and women are 
asymptomatic [8]. This high number of unrecognized infected 
individuals provide the reservoir for spreading the infection to 
other men and women via sexual intercourse.
Several laboratory methods are used for the diagnosis of C. 
trachomatis, these include cytological tests for the detection of 
intracytoplasmic inclusion bodies, cell culture, Enzyme-linked 
immunosorbent assay (ELISA), Direct immuno- fluorescence 
(DIF) and DNA amplification via PCR [9].
PCR is more sensitive than cell culture, it has a high 
sensitivity and specificity when compared to other tests used 
for C. trachomatis diagnosis, such as direct IF and ELISA 
which may give  false positive results [6].
PCR procedure to detect C. trachomatis targets a cryptic 
chlamydial plasmid (pCT) or the gene of the major outer 
membrane (MOMP) as templates for PCR amplification [10].
Mycoplasmas and ureaplasmas, members of the family 
Mycoplasmataceae of the class Mollicutes, are widely 
distributed in humans, mammals, birds, reptiles, fish and other 
vertebrates as well as plants [11].
Up to now,13 species of Mycoplasma and 2 species of 
Ureaplasma have been isolated in humans [12,13]. Three of 
these species Mycoplasma genitalium,  Ureaplasma parvum 
and Ureaplasma urealyticum, are thought to be associated 
with genitourinary infections [12,14].
M. genitalium was first isolated from men with urethritis, 
but studies that attempted to assess its association with disease 
were inhibited by the difficulty of growing the organism in 
culture. Currently the microorganism is detected mainly by 
PCR [15,16].
M. hominis has been associated with bacterial vaginosis, 
PID, post-partum fever and post-abortal fever, as well as a 
number of gynecological infections [12,17,18].
Detection of Mycoplasmas  employs the 16s rRNA gene 
for PCR amplification [19].
There is an increasing evidence that U. urealyticum is 
associated with a range of human disorders including non-
gonococcal urethritis (NGU) [20]. Previously U. urealyticum 
has been differentiated into biovars 1 and 2.  In 1998 U. 
urealyticum biovars 1 and 2 were classified into U. urealyticum 
and U. parvum, respectively [21].
At present, the main method of detecting Ureaplasmas is 
by culture, but the organism is difficult to isolate and requires 
special culture media [21].
Detection of ureaplasmas by PCR employs urease gene as 
template for amplification [22].
The goal of the present study was to detect  C. 
trachomatis,  M. genitalium, M. hominis and U. urealyticum 
in urine specimens of 200 patients with sterile pyuria by PCR. 
It is worth mentioning that no previous studies have been 
conducted on this topic in Gaza strip. This study is important 
in identifying the etiological agents for many of sterile pyuria 
cases and would be helpful in choosing the correct treatment.
MATERIALS AND METHODS
Patient selection: Between February 2006 to April 2007, all 
mid-stream specimens of urine received by the microbiology 
laboratory of the Al-Shifa hospital, Gaza. Most patients had 
symptoms and signs compatible with urethral discharge and 
urinary tract infection including dysuria, pollakiuria, and 
nocturia. All samples were  tested for routine urinalysis and 
culture were considered for inclusion in the study. Urine 
samples from which bacteria were isolated were excluded. 
All other sterile pyuria samples from men and women patients 
aged between 16 and 65 years were included. All urine samples 
were analyzed for routine urine examination, any sample 
containing more than 10 leukocytes / HPF was cultured on 
MacConkey agar, blood agar, and sabouraud agar to detect the 
presence of bacteria and Candida. A total of 200 sterile pyuria 
samples were negative for culture  (showing no significant 
growth after 24 hr) were included in the study. 
Table 1. Sequences of the primers used in PCR.
Organism Primer name Sequence 5’ to 3' Reference
M. genitalium MgPaW1* 5-AAG TGG AGC GAT CAT TAC TAA C-3 [39]
MgPaR1* 5-CCG TTG TTA TCA TAC CTT CTG A-3
M. hominis MHF* 5-ATA CAT CGA TGT CGA GCG AG-3 [43]
MHR* 5-CAT CTT TTA GTG GCG CCT TAC-3
C. trachomatis CTR 5-GCA AGA TAT CGA GTA TGC GTT GTT AGG-3 **
CTF 5-TTC ATT GTA CTC ATT AAA CGA GGC GG-3
U. urealyticum U5* 5-CAA TCT GCT CGT GAA GTA TTA C-3 [22]
U4* 5-ACG ACG TCC ATA AGC AAC T-3
*(All primers were synthesized by operon Biotechnologies, Germany).
**(These primers were included in C. trachomatis cryptic plasmid, primer set kit) Maxim Biotech, Inc. San Francisco USA
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Collection of samples: Subjects were asked not to void 
urine for 1 hour before urine collection and then to collect 20- 
50 ml of the first portion of voided urine (FVU) in a sterile 
plastic, screw-capped cups. The urine specimens were stored 
frozen at (-700C) for 4 to 6 days until processing.
DNA extraction: The urine specimens were thawed at 
room temperature. The urine specimens were briefly vortexed 
before being processed into the respective assay reagents. 
For DNA isolation, 1 ml of urine was transferred to a 1.5-ml 
microcentrifuge tube and centrifuged at 13000 rpm for 30 
min at room temperature.  After removal of the supernatant, 
the pellet was resuspended in 1 ml of urine resuspension 
buffer provided with the MasterPure DNA Purification Kit 
(EPICENTRE Technologies, USA) and the specimens were 
processed following the manufacturer’s instructions.
PCR primers: Oligonucleotide primers for the PCR were 
adapted from the published nucleotide sequences, and are 
shown in Tab. 1.
Detection of Chlamydia trachomatis by PCR: The DNA 
specimens were tested by the Chlamydia trachomatis cryptic 
plasmid, using primer set kit (Tab. 1), (10.0 µl) of the prepared 
DNA template or control  DNA  were added to 40.0 µl of 
Master Mixture in 0.2 ml thin walled microfuge tube. DNA 
amplification was carried out in a Eppendorf Mastercycler 
using an initial denaturation step of 96°C for 1 min, followed 
by 35 cycles of  denaturation at 94°C for 60 s, annealing at 
58°C for 60 s, and extension at 72°C for 60 s, ending with 
a final extension at 72°C for 10 min. Ten microliter of the 
amplified samples were subjected to electrophoresis in 1.5% 
agarose gel containing 0.5 µg/ml ethidium bromide. A band of 
364 base pairs in size was considered a positive result.
Detection of of M. genitalium by PCR: Five microliters 
of DNA was added to 25µl PCR master mix, 4µl Primer1 
MgpaW1 and 4µl Primer2 MgpaR. DNA amplification was 
carried out using an initial denaturation at 95° C for 10 minutes, 
35 cycles of:  denaturation at 94° C for 40 seconds, annealing 
at 56° C for 40 seconds, elongation at 72° C for 40 seconds 
and final extension at 72° C for 15 minutes. Upon completion 
of PCR, 20µl of the PCR  products were analyzed by ethidium 
bromide stained 2% agarose gel electrophoresis. The expected 
size of DNA fragment amplified using the specific primers in 
this kit is 495 bp.
Detection of M. hominis by PCR: Reaction mixture was 
prepared in a PCR tube by combining the reagents as described 
Figure 1. Aphotograph of ethidium bromide stained 2% agarose gel.
1-a 1-b
1-c 1-d
Figure 1-a. A PCR result for identification of C. trachomatis targeting  cryptic plasmid. M:100bp DNA marker, lane1: positive control, lane2: 
negative control, lane3 to lane7: positive samples with 364bp product. Figure 1.b. A PCR result for identification of M. hominis targeting 16s 
rRNA gene. M: 100bp DNA marker, lane1: negative control, Lanes 3, 4, 7: negative samples, lanes2, 5, 6: positive samples with 270bp product 
. Figure 1.c. A PCR result for identification of M. genitalium. M : 100bp DNA marker, lane1: negative control, lane2 : positive sample with 
495bp product, lane3 : negative sample  Figure 1.d. A PCR result for identification of  U. urealyticum targeting the urease gene. M : 100 bp DNA 
marker, lan2: negative control, lanes1, 3, 4, 5 : positive samples with 429bp product
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for M. genitalium except that primers MHR and MHF were 
used instead. PCR tubes were then placed in a thermal cycler 
and PCR amplification was done as described for M. genitalium 
except that the annealing temperature was 58° C. A positive 
PCR test should yield a 270 bp DNA fragment.
Detection of U. urealyticum by PCR: Reaction mixture 
was prepared in a PCR tube by combining the reagents as 
described for M. genitalium but using primers u4 and u5. DNA 
amplification was carried out using an initial denaturation at 
94° C for 2 minutes, 50 cycles of  denaturation at 94° C for 
30 seconds, annealing at 56° C for 1 minute, elongation at 72° 
C  for 45 seconds and final extension at 72° C for 5 minutes A 
positive PCR test should yield a 429 bp DNA fragment.
Data analysis: The data were  analyzed by a personal 
computer using SPSS 8.0. Differences in proportions 
were assessed by Chi–square test and p values < 0.05 were 
considered statistically significant.
RESULTS
In the present study 200 urine samples from patients with 
sterile pyuria (96 male , 104 female) aged > 18 years in 
Gaza, Palestine were subjected to PCR for detection of C. 
trachomatis, U. urealyticum, M. hominis and  M. genitalium. 
The results can be summarized as follows: Occurrence of C. 
trachomatis, U. urealyticum, M. hominis and M. genitalium C. 
trachomatis was detected in 20 samples (10%) (Fig. 1-a), U. 
urealyticum in 10 samples (5%) (Fig. 1-b), M. hominis  in 6 
samples (3%) (Fig. 1-c) and M. genitalium in 2 samples (1%) 
(Fig. 1-d), (Tab. 2).
Ninety six samples (48%) were from male patients and 
104 (52%) from female patients. The occurrence of the 
investigated microorganisms with regard to gender of patients 
is presented in Tab. 2. The difference in occurrence of C. 
trachomatis was statistically insignificant between males and 
females but, that of U. urealyticum was significant. M. hominis 
was detected only in samples collected from female patients. 
On the contrary, M. genitalium was detected only in men.
DISCUSSION
Sterile pyuria  in patients with clinical symptoms consistent 
with UTI can be a diagnostic challenge and warrants further 
investigation  for detection of fastidious and atypical 
microorganisms such as  C. trachomatis, M. hominis, M. 
genitalium, and U. urealyticum. These microorganisms are 
associated with various diseases of the genitourinary tract, 
but they are usually not detected by routine microbiological 
diagnosis.
C. trachomatis, M. hominis, M. genitalium, and U. 
urealyticum organisms are not screened by routine examination 
of urine samples in health laboratories in Gaza strip, and this is 
the first study that employed PCR assay for detection of these 
organisms in sterile pyuria specimens in Gaza strip.
Findings of this study showed that PCR testing of sterile 
pyuria could identify a significant number of causative 
microorganisms and should demonstrate to the clinicians the 
advantage of detection of the fastidious microorganisms in 
urine from the patients with UTI symptoms, when standard 
cultures fail to detect microbial infection. Since the detection 
of those microorganisms should constitute an essential part of 
the diagnosis and management of patients.  The association of 
sterile pyuria with these organisms infections, however, ought 
to  be discussed.
C. trachomatis infections are the most prevalent sexually 
transmitted bacterial infections among women and men 
worldwide [23]. Screening for these infections is important 
not only to identify infected symptomatic individuals for 
the diagnosis and management of their infections but also to 
identify asymptomatic individuals who serve as reservoirs for 
C. trachomatis infections [23].
Traditionally, the gold standard for the identification of 
C. trachomatis is culture, however, culture is time-consuming 
and labor-intensive. It takes 3 to 6 days to complete, and it 
requires access to specialized facilities and trained personnel 
[24].
ELISAs have also been evaluated as screening tests for the 
rapid identification of infected individuals by using first-catch 
urine [25]. ELISAs are relatively fast and easy to complete, but 
sensitivities of the tests for urine specimens remain relatively 
low [26].
In the current study, the occurrence of chlamydial 
infection was 10% in the 200 urine specimens collected 
Table 2. Microorganisms identified in the 200 studied specimens.
Microorganisms
male female total P value
n (%) n (%) n (%)
C. trachomatis 11 (5.5) 9 (4.5) 20 (10.0) 0.509
U. urealyticum 1 (0.5) 9 (4.5) 10 (5.0) 0.008*
M. hominis 0 (0.0) 6 (3.0) 6 (3.0) 0.005*
M. genitalium 2 (1.0) 0 (0.0) 2 (1.0) 0.085
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from symptomatic patients with sterile pyuria. In samples 
from women (104 samples) C. trachomatis was detected in 9 
samples (8.7%) and in 11 of the 96 male specimens (11.5%). 
The difference in occurrence was statistically insignificant 
(P=0.509) between males and females.
Our results revealed that the occurrence of C. trachomatis 
was higher than the occurrence of the other microorganisms 
detected in this study. These results suggest that C. trachomatis 
infection should be strongly considered in urine samples that 
show sterile pyuria.
This is congruent with the conclusion of Basarab et al. 
(2002) who showed that a significant number of C. trachomatis 
could be detected in urine specimens from sterile pyuria [27].
When compared to other studies from other countries, our 
results are still lower than that reported in Egypt (31%), Iran 
(22%), India (30.8%) and the UK (21%). However, our results 
is higher than that reported in Jordan (4.6%), and Ghana 
(3.0%) [28-32].
Variations of Chlamydia prevalence between countries 
and studies could be due to several factors such as, study 
population (selection of high risk group, symptoms, education 
level, sample size, etc.), rate of infection in the study area, 
hygiene level and socioeconomic status of the study area, 
culture of the society whether it is open or conservative, and 
the technique and the DNA target of PCR used.
Mycoplasma hominis is a heterogeneous genital 
mycoplasma [33] found in at least two-thirds of women with 
bacterial vaginosis (BV), compared to 10% of healthy women 
[34]. However, its role as a primary pathogen is doubtful since 
it co-exists with many other bacteria in BV [35].
Culture is the most commonly employed method for 
detection of genital Mycoplasma, but it requires special 
handling, complex media, and cultivation. Furthermore, positive 
samples need further testing to determine the species [36].
Comparison between culture method and PCR has been 
performed and showed that a PCR assay was as sensitive as 
culture for detection of M. hominis from clinical samples. In 
addition it was very specific [37].
The results showed that M. hominis was present in 6 
samples (3%). The occurrence of M. hominis among women 
was 5.8% and it was not detected in men. This finding deserves 
further investigation to determine whether M. hominis has 
a role in disease or just in colonization and to improve the 
association of sterile pyuria with urogenital M. hominis 
infection or colonization.
M. genitalium was first isolated in urethral cultures from 
two men with NGU in 1980 [13]. Although M. genitalium 
has been proposed as a cause of human NGU, the precise 
role of this mycoplasma in the etiology of NGU has not been 
established because of the immense difficulty of isolating it 
from clinical samples.
The results showed that the occurrence of M. genitalium 
was 1% and it was detected in men only. The detection of 
M. genitalium in urine samples of 2 of 96 men (2.1%)  with 
UTI symptoms and sterile pyuria by PCR in this study and 
previous studies that used these assays should be considered 
an evidence for the association between urethritis in men and 
M. genitalium infection.
When compared to the results of other studies, our findings 
are similar to those reported by Takahashi et al. (2006) in 
Japan, where they recorded a 1%   prevalence of M. genitalium 
among men [38].
Our results, however,  are considerably lower than reported 
by Leandro et al. (2002) in the USA, where they examined 
the prevalence of   M. genitalium in men with urethritis at 
(STDs) clinic in New Orleans (97 men with urethritis and 
184 asymptomatic men) by PCR, the results of their study 
showed that M. genitalium infection rates in symptomatic 
and asymptomatic men were 25% and 7%, respectively. The 
authors concluded that M. genitalium is associated with (NGU) 
in that population [39].
In Japan,   Maedo et al. (2004) reported that the prevalence 
of M. genitalium was 17.0% in first-voided urine specimens 
from153 male patients with NGU [40].
The difference between our results and those reported by 
previous studies may be due to the difference in the populations 
studied and the prevalence of the microorganism in the study 
area.
Another issue that needs further investigation is the role 
of M. genitalium in genital tract inflammatory disease in 
women.
U. urealyticum has been shown to be associated with NGU 
[20]. At present, the main method of detecting U. urealyticum 
is by culture, but the organism is difficult to isolate and 
requires special culture media. U. urealyticum can also be 
detected rapidly and accurately by PCR such that treatment 
may be established in the early stages of infection, also this 
method avoids the problems associated with culturing.
In the present study U. urealyticum was  detected in 
9 (8.7%) of female samples and in only one (1%) of the 
male sample. The difference in occurrence was statistically 
significant (P=0.008) between males and females.
Detection of the microorganism in urine specimens leaves 
the clinical significance of U. urealyticum  open to question. It 
should be noted that 60% of healthy women carry U. urealyticum 
in their urogenital tract. Unlikely, in male urogenital tract this 
microorganism should not appear. If present in male urethra, it 
should always be treated as a pathogen [41].
It is known that other organisms can cause the clinical 
disorders observed and also that not all serotypes of U. 
urealyticum are pathogenic.
When we compared our results to other studies, our results 
are still lower than those reported in Japan (16.3%) , China 
(24%) and Austria (20%) [4,40,42].
These variations could be explained by differences in 
the study population and rate of infection in the study area. 
Previous studies have included populations that have much 
higher incidences and prevalences of STD than does the 
population of our study.
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Finally, Mycoplasmas, Ureaplasmas and C. trachomatis 
are associated with sterile pyuria in Gaza Strip , PCR assay 
provide a rapid and effective measure to detect fastidious and 
atypical microorganisms in sterile pyuria cases which is useful 
for identification of etiological agents and  the consequent 
management and treatment of patients.
Further investigations should be done including 
asymptomatic cases and symptomatic without sterile pyuria to 
compare the prevalence of these microorganisms among these 
groups. STDs clinics are not available, it recommended to 
establish such clinics to minimize the danger of such diseases. 
We also recommend the establishment of a database for STDs 
in Gaza strip.
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